Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia
OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episode patients with schizophrenia were treated with a...
Gespeichert in:
| Veröffentlicht in: | The American journal of psychiatry 2002-07, Vol.159 (7), p.1230-1232 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1232 |
|---|---|
| container_issue | 7 |
| container_start_page | 1230 |
| container_title | The American journal of psychiatry |
| container_volume | 159 |
| creator | Cannon, Tyrone D. Huttunen, Matti O. Dahlström, Minna Larmo, Ilkka Räsänen, Pirkko Juriloo, Alo |
| description | OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episode patients with schizophrenia were treated with average doses of 1.0 and 1.8 mg day of risperidone, respectively, in an 8- to 12-week open-label trial. RESULTS: No significant treatment-related adverse events were noted. Severity of thought and behavior disturbance ratings declined by about 30%; performance on a test of verbal learning improved by about 100% during treatment in both prodromal and first-episode patients, changes that achieved statistical significance despite the small group sizes. CONCLUSIONS: These findings are preliminary and should not be used to guide health care decisions at this time. Randomized controlled trials are needed to determine whether antipsychotic drug treatment of prodromal patients can delay or prevent onset or attenuate the clinical course of schizophrenia. |
| doi_str_mv | 10.1176/appi.ajp.159.7.1230 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71864113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71864113</sourcerecordid><originalsourceid>FETCH-LOGICAL-a430t-2397c199254b1f4f6bbf06371215eaf2ba65f68dfc80807d59e3d84db3b27b593</originalsourceid><addsrcrecordid>eNqFkd9L3TAUgMNQ5tXtLxhIEfStXU7SNO2jeDcVBIVdwbeQpsmaS9vUpH24_vW2u8ULe9geDuHAd37lQ-gb4ASAZ99l39tEbvsEWJHwBAjFn9AKGGUxJyQ_QiuMMYkLRl9O0GkI2ynFlJPP6AQILqZgK7S-7gbbh52q3WBVtPbj72jjtRxa3Q2R7aKh1tGTd5V3rWyip1oGHTkT_VK1fXN97XVn5Rd0bGQT9NflPUPPP39sbu7ih8fb-5vrh1imFA8xoQVXUBSEpSWY1GRlaXBGORBgWhpSyoyZLK-MynGOecUKTas8rUpaEl6ygp6hq33f3rvXUYdBtDYo3TSy024MgkOepQD0vyDjKQWaz-DFX-DWjb6bjhCE4JRjCtkE0T2kvAvBayN6b1vpdwKwmFWIWYWYVIhJheBiVjFVnS-tx7LV1aFm-fsJuFwAGZRsjJedsuHAUZ5njM074j33Z8rHfv-a_Q6XbaHn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220470316</pqid></control><display><type>article</type><title>Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Cannon, Tyrone D. ; Huttunen, Matti O. ; Dahlström, Minna ; Larmo, Ilkka ; Räsänen, Pirkko ; Juriloo, Alo</creator><creatorcontrib>Cannon, Tyrone D. ; Huttunen, Matti O. ; Dahlström, Minna ; Larmo, Ilkka ; Räsänen, Pirkko ; Juriloo, Alo</creatorcontrib><description>OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episode patients with schizophrenia were treated with average doses of 1.0 and 1.8 mg day of risperidone, respectively, in an 8- to 12-week open-label trial. RESULTS: No significant treatment-related adverse events were noted. Severity of thought and behavior disturbance ratings declined by about 30%; performance on a test of verbal learning improved by about 100% during treatment in both prodromal and first-episode patients, changes that achieved statistical significance despite the small group sizes. CONCLUSIONS: These findings are preliminary and should not be used to guide health care decisions at this time. Randomized controlled trials are needed to determine whether antipsychotic drug treatment of prodromal patients can delay or prevent onset or attenuate the clinical course of schizophrenia.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.159.7.1230</identifier><identifier>PMID: 12091205</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adolescent ; Adolescents ; Adult ; Antipsychotic Agents - administration & dosage ; Antipsychotic Agents - therapeutic use ; Antipsychotic drugs ; Biological and medical sciences ; Clinical outcomes ; Drug Administration Schedule ; Drug therapy ; Family ; Female ; Finland - epidemiology ; First time ; Humans ; Male ; Medical sciences ; Neuropharmacology ; Neuropsychological Tests ; Pharmacology. Drug treatments ; Prodromal symptoms ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Risperidone - administration & dosage ; Risperidone - therapeutic use ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - epidemiology ; Schizophrenic Psychology ; Severity of Illness Index ; Treatment Outcome ; Verbal Learning</subject><ispartof>The American journal of psychiatry, 2002-07, Vol.159 (7), p.1230-1232</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright American Psychiatric Association Jul 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a430t-2397c199254b1f4f6bbf06371215eaf2ba65f68dfc80807d59e3d84db3b27b593</citedby><cites>FETCH-LOGICAL-a430t-2397c199254b1f4f6bbf06371215eaf2ba65f68dfc80807d59e3d84db3b27b593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.159.7.1230$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.159.7.1230$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2842,21605,21606,21607,27901,27902,30977,77537,77542</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13786553$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12091205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cannon, Tyrone D.</creatorcontrib><creatorcontrib>Huttunen, Matti O.</creatorcontrib><creatorcontrib>Dahlström, Minna</creatorcontrib><creatorcontrib>Larmo, Ilkka</creatorcontrib><creatorcontrib>Räsänen, Pirkko</creatorcontrib><creatorcontrib>Juriloo, Alo</creatorcontrib><title>Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episode patients with schizophrenia were treated with average doses of 1.0 and 1.8 mg day of risperidone, respectively, in an 8- to 12-week open-label trial. RESULTS: No significant treatment-related adverse events were noted. Severity of thought and behavior disturbance ratings declined by about 30%; performance on a test of verbal learning improved by about 100% during treatment in both prodromal and first-episode patients, changes that achieved statistical significance despite the small group sizes. CONCLUSIONS: These findings are preliminary and should not be used to guide health care decisions at this time. Randomized controlled trials are needed to determine whether antipsychotic drug treatment of prodromal patients can delay or prevent onset or attenuate the clinical course of schizophrenia.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adult</subject><subject>Antipsychotic Agents - administration & dosage</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic drugs</subject><subject>Biological and medical sciences</subject><subject>Clinical outcomes</subject><subject>Drug Administration Schedule</subject><subject>Drug therapy</subject><subject>Family</subject><subject>Female</subject><subject>Finland - epidemiology</subject><subject>First time</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neuropsychological Tests</subject><subject>Pharmacology. Drug treatments</subject><subject>Prodromal symptoms</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Risperidone - administration & dosage</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - epidemiology</subject><subject>Schizophrenic Psychology</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><subject>Verbal Learning</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqFkd9L3TAUgMNQ5tXtLxhIEfStXU7SNO2jeDcVBIVdwbeQpsmaS9vUpH24_vW2u8ULe9geDuHAd37lQ-gb4ASAZ99l39tEbvsEWJHwBAjFn9AKGGUxJyQ_QiuMMYkLRl9O0GkI2ynFlJPP6AQILqZgK7S-7gbbh52q3WBVtPbj72jjtRxa3Q2R7aKh1tGTd5V3rWyip1oGHTkT_VK1fXN97XVn5Rd0bGQT9NflPUPPP39sbu7ih8fb-5vrh1imFA8xoQVXUBSEpSWY1GRlaXBGORBgWhpSyoyZLK-MynGOecUKTas8rUpaEl6ygp6hq33f3rvXUYdBtDYo3TSy024MgkOepQD0vyDjKQWaz-DFX-DWjb6bjhCE4JRjCtkE0T2kvAvBayN6b1vpdwKwmFWIWYWYVIhJheBiVjFVnS-tx7LV1aFm-fsJuFwAGZRsjJedsuHAUZ5njM074j33Z8rHfv-a_Q6XbaHn</recordid><startdate>20020701</startdate><enddate>20020701</enddate><creator>Cannon, Tyrone D.</creator><creator>Huttunen, Matti O.</creator><creator>Dahlström, Minna</creator><creator>Larmo, Ilkka</creator><creator>Räsänen, Pirkko</creator><creator>Juriloo, Alo</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7QJ</scope><scope>7X8</scope></search><sort><creationdate>20020701</creationdate><title>Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia</title><author>Cannon, Tyrone D. ; Huttunen, Matti O. ; Dahlström, Minna ; Larmo, Ilkka ; Räsänen, Pirkko ; Juriloo, Alo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a430t-2397c199254b1f4f6bbf06371215eaf2ba65f68dfc80807d59e3d84db3b27b593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adult</topic><topic>Antipsychotic Agents - administration & dosage</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic drugs</topic><topic>Biological and medical sciences</topic><topic>Clinical outcomes</topic><topic>Drug Administration Schedule</topic><topic>Drug therapy</topic><topic>Family</topic><topic>Female</topic><topic>Finland - epidemiology</topic><topic>First time</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neuropsychological Tests</topic><topic>Pharmacology. Drug treatments</topic><topic>Prodromal symptoms</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Risperidone - administration & dosage</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - epidemiology</topic><topic>Schizophrenic Psychology</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><topic>Verbal Learning</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cannon, Tyrone D.</creatorcontrib><creatorcontrib>Huttunen, Matti O.</creatorcontrib><creatorcontrib>Dahlström, Minna</creatorcontrib><creatorcontrib>Larmo, Ilkka</creatorcontrib><creatorcontrib>Räsänen, Pirkko</creatorcontrib><creatorcontrib>Juriloo, Alo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cannon, Tyrone D.</au><au>Huttunen, Matti O.</au><au>Dahlström, Minna</au><au>Larmo, Ilkka</au><au>Räsänen, Pirkko</au><au>Juriloo, Alo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2002-07-01</date><risdate>2002</risdate><volume>159</volume><issue>7</issue><spage>1230</spage><epage>1232</epage><pages>1230-1232</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>OBJECTIVE: The safety and tolerability of short-term treatment with a low dose of risperidone was evaluated in adolescents with prodromal symptoms and a family history of schizophrenia. METHOD: Four prodromal high-risk adolescents and six first-episode patients with schizophrenia were treated with average doses of 1.0 and 1.8 mg day of risperidone, respectively, in an 8- to 12-week open-label trial. RESULTS: No significant treatment-related adverse events were noted. Severity of thought and behavior disturbance ratings declined by about 30%; performance on a test of verbal learning improved by about 100% during treatment in both prodromal and first-episode patients, changes that achieved statistical significance despite the small group sizes. CONCLUSIONS: These findings are preliminary and should not be used to guide health care decisions at this time. Randomized controlled trials are needed to determine whether antipsychotic drug treatment of prodromal patients can delay or prevent onset or attenuate the clinical course of schizophrenia.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>12091205</pmid><doi>10.1176/appi.ajp.159.7.1230</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-953X |
| ispartof | The American journal of psychiatry, 2002-07, Vol.159 (7), p.1230-1232 |
| issn | 0002-953X 1535-7228 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71864113 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; American Psychiatric Publishing Journals (1997-Present); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adolescent Adolescents Adult Antipsychotic Agents - administration & dosage Antipsychotic Agents - therapeutic use Antipsychotic drugs Biological and medical sciences Clinical outcomes Drug Administration Schedule Drug therapy Family Female Finland - epidemiology First time Humans Male Medical sciences Neuropharmacology Neuropsychological Tests Pharmacology. Drug treatments Prodromal symptoms Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Risperidone - administration & dosage Risperidone - therapeutic use Schizophrenia Schizophrenia - drug therapy Schizophrenia - epidemiology Schizophrenic Psychology Severity of Illness Index Treatment Outcome Verbal Learning |
| title | Antipsychotic Drug Treatment in the Prodromal Phase of Schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T12%3A16%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antipsychotic%20Drug%20Treatment%20in%20the%20Prodromal%20Phase%20of%20Schizophrenia&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Cannon,%20Tyrone%20D.&rft.date=2002-07-01&rft.volume=159&rft.issue=7&rft.spage=1230&rft.epage=1232&rft.pages=1230-1232&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.159.7.1230&rft_dat=%3Cproquest_cross%3E71864113%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220470316&rft_id=info:pmid/12091205&rfr_iscdi=true |